CYP19A1 and breast carcinoma: The molecular docking simulations suggest that most of the dimeric photocompounds have lower EFEB values than key targets involved in breast cancer therapy (such as aromatase, ER, FGFR1, EGFR, and HER2) compared to CPZ and its monomeric photocompounds, indicating a potentially more effective cancer treatment at lower doses.